Oculis Holding AG

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

ZUG, Switzerland, and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD, CEO of Oculis, will participate at OIS Retina Innovation Summit, an event organized by Ophthalmology Innovation Source, on July 27, in Seattle, Washington. In addition to participating, Dr. Sherif will present an update on Oculis with a focus on the recently announced positive DIAMOND Phase 3 Stage 1 readout of OCS-01 eye drops for the treatment of Diabetic Macular Edema (DME) and associated next steps.

Oculis to Present at OIS Retina Innovation Summit

ZUG, Switzerland and BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that the underwriters of its previously announced public offering of ordinary shares, which closed on June 5, 2023, have partially exercised their option to purchase an additional 154,234 ordinary shares at a public offering price per share of $11.50, resulting in additional gross proceeds to Oculis of approximately $1.8 million. After giving effect to the issuance of these additional shares, which closed today, Oculis has sold a total of 3,654,234 ordinary shares in the offering for aggregate gross proceeds of approximately $42.0 million, before deducting underwriting discounts and commissions and offering expenses.

Oculis Announces Partial Exercise of Underwriters' Option to Purchase Additional Ordinary Shares

ZUG, Switzerland and BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced it has won the 2023 Knowledge Award from the Icelandic Association of Business and Economics.

Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics

Oculis is an “under-the-radar” biotech stock that is off to a strong start thanks to a lead drug candidate that could offer hope for diabetic macular edema (DME), according to Baird. Analysts are initiating coverage on the European-based company with an Outperform rating and a US$58 price target on the Nasdaq-listed stock.

Oculis could have a breakthrough treatment on its hands with an eye drop for DME

Rezolute

Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in the treatment of diabetic eye disease, including diabetic retinopathy (DR) and diabetic macular edema (DME). The report, Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease, highlights the unmet needs and the companies leading innovation in this field.

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

ZUG, Switzerland and BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will attend the 2023 Jefferies Global Healthcare Conference in New York, from Wednesday, June 7 to Friday, June 9 for 1:1 meetings and will deliver a corporate presentation, on Friday, June 9, 2023 at 11:00-11:25 AM Eastern Time in Track 8.

Oculis to Participate in Jefferies Healthcare Conference

ZUG, Switzerland and BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the pricing of a follow-on public offering of 3,500,000 ordinary shares at a public offering price of $11.50 per ordinary share, for gross proceeds of $40.25 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Oculis has granted the underwriters a 30-day option to purchase up to an additional 525,000 ordinary shares on the same terms and conditions. The offering is expected to close on or about June 5, 2023, subject to satisfaction of customary closing conditions.

Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares

ZUG, Switzerland and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the launch of a follow-on public offering of 5,000,000 ordinary shares. In addition, Oculis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of ordinary shares to be sold in the offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. All of the securities in the offering are to be sold by Oculis.

Oculis Announces Launch of Proposed Public Offering of Ordinary Shares

ZUG, Switzerland and BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that its Head of Development, Dr. Bastian Dehmel, will be participating in the 2023 EuDES (European Dry Eye Society) Meeting in Munich, Germany on June 2-3, 2023, where he will be presenting in the session “Future developments in Dry Eye” among other innovative companies and experts in Dry Eye Disease.

Oculis to Participate and Present at Upcoming EuDES Meeting

ZUG, Switzerland and BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive top line results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 eye drops in Diabetic Macular Edema (DME). DME is the leading cause of visual loss and legal blindness in patients with diabetes, affecting around 37 million people worldwide, with a significant number of patients left untreated due to a lack of convenient treatment options.

Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

ZUG, Switzerland and BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the nomination of its co-founders, Professors Einar Stefánsson and Thorsteinn Loftsson, as finalists in the ‘Research' category of the European Inventor Award 2023.

Oculis Co-founders Selected as Finalists in European Inventor Award 2023

ZUG, Switzerland, and BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the opening of its Boston, Massachusetts office, expanding its US presence in preparation of becoming an active player in the US market and demonstrating execution of its strategy.

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

ZUG, Switzerland and BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that members of management will be participating in the following April investor conferences:

Oculis to Participate at Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET.

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that it will ring the Nasdaq opening bell today to celebrate its public listing on the Nasdaq Stock Market earlier this month.

Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

LAUSANNE, Switzerland, March 16, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the completion of enrollment for its Phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01, a novel, high concentration, preservative-free, topical OPTIREACH formulation of dexamethasone for the treatment of inflammation and pain following cataract surgery.

Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

Closing of business combination with European Biotech Acquisition Corp. creates Nasdaq-listed ophthalmology company, under the ticker “OCS”, with advanced clinical-stage pipeline of multiple product candidates in key areas of medical needs such as retina, dry eye, and neuro-ophtha diseases

News for Oculis Holding AG Stock (OCS)